Open AccessE2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product.
Author(s) -
Erik K. Flemington,
Samuel H. Speck,
William G. Kaelin
Publication year - 1993
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.90.15.6914
Subject(s) - e2f , transactivation , retinoblastoma protein , transcription factor , microbiology and biotechnology , psychological repression , transcription (linguistics) , mutant , biology , dna binding domain , dna binding protein , binding site , chemistry , gene , gene expression , biochemistry , cell cycle , linguistics , philosophy
Previous studies have shown that the carboxyl-terminal region of E2F-1 (residues 368-437) can support transcriptional activation when linked to the DNA-binding domain of the yeast transcription factor GAL4. This region also contains an 18-residue retinoblastoma (RB)-binding sequence, raising the possibility that RB binding might inhibit the ability of E2F-1 to form protein-protein contacts required for activation. Here we report a further analysis of the E2F-1 activation domain. In addition, we show that overexpression of RB, but not the RB mutant, RBd22, can inhibit GAL4/E2F-1 activity in vivo. Moreover, expression of the simian virus 40 large tumor antigen (T antigen), but not the RB-binding defective T antigen point mutant, K1, can overcome this repression. Three different GAL4/E2F-1 mutants that activate transcription, but fail to bind to RB, are not significantly affected by overexpression of RB. These findings support a model wherein RB suppresses E2F-1-mediated transcriptional activation through direct physical association.